CAMBRIDGE, Mass.– Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership aimed at advancing cardiovascular research through expanded community-based clinical trials.
The collaboration will integrate USHV research sites into Iterative Health’s global network, which includes more than 100 sites across three continents. The move marks an expansion of Iterative Health’s focus beyond gastroenterology, hepatology, and obesity into cardiology, while strengthening USHV’s role in community-based cardiovascular research.
Robbie Allen, chief executive officer of US Heart & Vascular, said the partnership will help bring advanced therapies closer to patients.
“Clinical research is one of the most powerful ways we expand access, improve patient outcomes, and shape the future of cardiovascular care,” Allen said. “By partnering with Iterative Health, we are strengthening our ability to bring innovative therapies directly into the communities we serve. This collaboration ensures our physicians and patients have access to leading-edge trials while allowing US Heart & Vascular to remain focused on delivering exceptional, physician-led care.”
Under the agreement, USHV research sites will gain access to Iterative Health’s centralized operational infrastructure, including support for clinical trial operations, business development, and technology. The companies said the partnership is expected to reduce operational complexity while enabling physicians to offer more patients access to clinical trials and emerging therapies.
Dr. Thomas Waggoner, a structural cardiologist and medical director for clinical research at Pima Heart & Vascular, said expanding trials into community settings is key to improving access.
“Innovation in cardiovascular medicine shouldn’t be limited to a few academic centers,” Waggoner said. “By expanding community-based research across USHV, we’re ensuring more patients have access to clinical trials and breakthrough therapies close to home, where trusted relationships with their physicians already exist.”
The partnership also reinforces Iterative Health’s broader strategy to serve as a research partner across multiple therapeutic areas, including cardiology.
Jonathan Ng, founder and chief executive officer of Iterative Health, said the collaboration represents a major step for the company.
“Entering cardiology through our strategic partnership with US Heart & Vascular is a defining moment for Iterative Health and reflects the strength of our site-serving model,” Ng said. “Together, we are ensuring that thousands of patients have access to the newest available therapies, and that sponsors have a credible, high-performing partner to accelerate cardiovascular trial success.”
